Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Single and Multiple Dosing Study to Evaluate Pharmacokinetics and Pharmacodynamics of ASP3325 in Patients With Chronic Kidney Disease and Hyperphosphatemia Undergoing Hemodialysis

NCT02510274 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT02510274
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02510274 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Single and Multiple Dosing Study to Evaluate Pharmacokinetics and Pharmacodynamics of ASP3325 in Patients With Chronic Kidney Disease and Hyperphosphatemia Undergoing Hemodialysis
Lead sponsor
Astellas Pharma Inc
Phase
Phase 1
Overall status
Completed
Start date
May 12, 2014
Completion date
November 4, 2014
Enrollment
24 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, hyperphosphatemia undergoing hemodialysis